<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:56:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8601309" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8601309</identifier>
        <datestamp>2022-07-01</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8601309</article-id>
              <article-id pub-id-type="pmcid">PMC8601309</article-id>
              <article-id pub-id-type="pmc-uid">8601309</article-id>
              <article-id pub-id-type="pmid">34516759</article-id>
              <article-id pub-id-type="pmid">34516759</article-id>
              <article-id pub-id-type="publisher-id">JCO.21.01436</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.21.01436</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Gastrointestinal Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3915-7243</contrib-id>
                  <name>
                    <surname>Adams</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2512-2296</contrib-id>
                  <name>
                    <surname>Fisher</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graham</surname>
                    <given-names>Janet</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4379-6005</contrib-id>
                  <name>
                    <surname>Seligmann</surname>
                    <given-names>Jenny F.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2441-9629</contrib-id>
                  <name>
                    <surname>Seymour</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0189-8348</contrib-id>
                  <name>
                    <surname>Kaplan</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yates</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0166-1700</contrib-id>
                  <name>
                    <surname>Parmar</surname>
                    <given-names>Mahesh</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3993-5041</contrib-id>
                  <name>
                    <surname>Richman</surname>
                    <given-names>Susan D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3597-5444</contrib-id>
                  <name>
                    <surname>Quirke</surname>
                    <given-names>Philip</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Butler</surname>
                    <given-names>Rachel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6636-2010</contrib-id>
                  <name>
                    <surname>Brown</surname>
                    <given-names>Ewan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Collinson</surname>
                    <given-names>Fiona</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Falk</surname>
                    <given-names>Stephen</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6268-2030</contrib-id>
                  <name>
                    <surname>Wasan</surname>
                    <given-names>Harpreet</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="con12" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6202-9640</contrib-id>
                  <name>
                    <surname>Shiu</surname>
                    <given-names>Kai-Keen</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con13" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Middleton</surname>
                    <given-names>Gary</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con14" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8402-8670</contrib-id>
                  <name>
                    <surname>Samuel</surname>
                    <given-names>Leslie</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="con15" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8018-7730</contrib-id>
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Richard H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con16" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2827-6634</contrib-id>
                  <name>
                    <surname>Brown</surname>
                    <given-names>Louise C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                  <xref rid="con17" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0580-5065</contrib-id>
                  <name>
                    <surname>Maughan</surname>
                    <given-names>Timothy S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="con18" ref-type="fn"/>
                </contrib>
                <on-behalf-of>on behalf of the FOCUS4 Trial Investigators</on-behalf-of>
                <aff id="aff1"><label><sup>1</sup></label>Centre for Trials Research Cardiff University and Velindre NHS Trust, Cardiff, United Kingdom</aff>
                <aff id="aff2"><label><sup>2</sup></label>MRC Clinical Trials Unit at UCL, London, United Kingdom</aff>
                <aff id="aff3"><label><sup>3</sup></label>University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom</aff>
                <aff id="aff4"><label><sup>4</sup></label>Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom</aff>
                <aff id="aff5"><label><sup>5</sup></label>Bristol Genetics Laboratory, Bristol, United Kingdom</aff>
                <aff id="aff6"><label><sup>6</sup></label>Western General Hospital, Edinburgh, United Kingdom</aff>
                <aff id="aff7"><label><sup>7</sup></label>Bristol Cancer Institute, Bristol, United Kingdom</aff>
                <aff id="aff8"><label><sup>8</sup></label>Hammersmith Hospital London, London, United Kingdom</aff>
                <aff id="aff9"><label><sup>9</sup></label>University College Hospital London, London, United Kingdom</aff>
                <aff id="aff10"><label><sup>10</sup></label>University of Birmingham, Birmingham, United Kingdom</aff>
                <aff id="aff11"><label><sup>11</sup></label>Aberdeen Royal Infirmary, Aberdeen, United Kingdom</aff>
                <aff id="aff12"><label><sup>12</sup></label>MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Louise C. Brown, PhD, University College London, MRC Clinical Trials Unit, 90 High Holborn, London WC1V 6LJ, United Kingdom; e-mail: <email>l.brown@ucl.ac.uk</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>39</volume>
              <issue>33</issue>
              <fpage>3693</fpage>
              <lpage>3704</lpage>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>4</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>Licensed under the Creative Commons Attribution 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-39-3693.pdf"/>
              <abstract>
                <title>PURPOSE</title>
                <p>Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in patients who are responding to first-line therapy.</p>
                <sec>
                  <title>METHODS</title>
                  <p>FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed mCRC. The FOCUS4-N trial was offered to patients in whom a targeted subtrial was unavailable or biomarker tests failed. Patients were randomly assigned using a 1:1 ratio between maintenance capecitabine and active monitoring (AM). The primary outcome was progression-free survival (PFS) with secondary outcomes including OS toxicity and tolerability.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>Between March 2014 and March 2020, 254 patients were randomly assigned (127 to capecitabine and 127 to AM) across 88 UK sites. Baseline characteristics were balanced. There was strong evidence of efficacy for PFS (hazard ratio = 0.40; 95% CI, 0.21 to 0.75; <italic toggle="yes">P</italic> &lt; .0001), but no significant improvement in OS (hazard ratio, 0.93; 95% CI, 0.69 to 1.27; <italic toggle="yes">P</italic> = .66) was observed. Compliance with treatment was good, and toxicity from capecitabine versus AM was as expected with grade ≥ 2 fatigue (25% <italic toggle="yes">v</italic> 12%), diarrhea (23% <italic toggle="yes">v</italic> 13%), and hand-foot syndrome (26% <italic toggle="yes">v</italic> 3%). Quality of life showed little difference between the groups.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>Despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients who are stable or responding to first-line treatment for mCRC. Capecitabine without bevacizumab may be used to extend PFS in the interval after 16 weeks of first-line therapy.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="7"/>
                <table-count count="4"/>
                <equation-count count="0"/>
                <ref-count count="10"/>
                <page-count count="0"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Treatment breaks in patients receiving palliative chemotherapy for metastatic colorectal cancer (mCRC) reduce toxicity burden and improve quality of life (QoL).<sup><xref rid="b1" ref-type="bibr">1</xref></sup> However, current standards either mandate or recommend a strategy of continuing therapy, until progression or excess toxicity. Standard maintenance strategies in high-income countries favor combined oral capecitabine with intravenous bevacizumab once every 3 weeks,<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref></sup> on the basis of the phase III CAIRO3<sup><xref rid="b4" ref-type="bibr">4</xref></sup> and AIO-0207<sup><xref rid="b5" ref-type="bibr">5</xref></sup> studies. Health economic evaluation of this approach has previously indicated a lack of cost-effectiveness driven by nonsignificant improvement in overall survival (OS) and high costs of intravenous bevacizumab (drug plus administration).<sup><xref rid="b6" ref-type="bibr">6</xref></sup> Previous studies have evaluated a range of strategies to either completely stop therapy as a treatment holiday, reducing toxicities and hospital visits, or attenuate therapy, removing certain drugs as a maintenance therapy in comparison with historic standard-of-care continuation of maximum tolerated dose of treatment. Meta-analysis of these approaches overall shows no difference in OS.<sup><xref rid="b7" ref-type="bibr">7</xref></sup> Notably, maintenance strategies, almost uniformly, demonstrate an improvement in progression-free survival (PFS), but at the expense of ongoing (though attenuated) toxicity and unending multiple hospital visits for intravenous therapy. In the FOCUS4-N trial (embedded within the FOCUS4 trial program, see the Data Supplement [online only]), we have explored the oral strategy of capecitabine only versus active monitoring (AM). This will allow us to study the potential impact on PFS, toxicity, and QoL, which will enable patients and clinicians to choose an optimum approach tailored to the individual.</p>
              <boxed-text id="B1" position="anchor">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>In patients with metastatic colorectal cancer, first-line systemic anticancer therapy (SACT) with palliative intent aims to extend overall survival (OS) while maintaining quality of life. Current guidelines recommend a maintenance strategy of oral capecitabine and bevacizumab in patients with disease control after 4-6 months of induction SACT. This is based upon improved progression-free survival (without evidence of OS benefit) compared with a complete treatment break with active monitoring (AM). FOCUS4-N aims to establish the impact of maintenance capecitabine monotherapy versus AM.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>These results demonstrate that capecitabine can double the time until return to induction SACT. However, patients may adopt an AM approach without detriment in OS and with less toxicity.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>FOCUS4-N provides information for patients and clinicians, which will assist decision making at the end of induction SACT. Capecitabine without intravenous bevacizumab is likely more cost-effective than the current recommended approach of capecitabine and bevacizumab.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>The FOCUS4 trial program is a molecularly stratified umbrella platform trial (Data Supplement) that evaluated safety and efficacy of novel treatments in targeted biomarker subgroups within a phase II or III trial setting. The trial used adaptive statistical methodology that allowed the addition of new therapies and the dropping of ineffective ones and including a nonstratified comparison (FOCUS4-N) for patients in whom a molecularly stratified comparison was unavailable or the biomarker tests failed for their tumor tissue. In the Data Supplement, we describe the design and methods for patient registration and biomarker testing. In this article, we report the findings of FOCUS4-N, which tested the efficacy of capecitabine as a maintenance therapy versus AM in patients with mCRC.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec sec-type="subjects">
                <title>Trial Approvals, Patient Eligibility, and Recruitment</title>
                <p>The trial and subsequent amendments were approved by the UK National Ethics Committee Oxford (reference 13/SC/0111) and by the relevant regulatory body MHRA (CTA# 20363/0400/001 and EudraCT# 2012-005111-12).</p>
                <p>Patients age at least 18 years with newly diagnosed locally advanced or mCRC were eligible for registration in the FOCUS4 trial program (see the Data Supplement for details of FOCUS4 design and registration methods). Patients whose tumors had remained stable or responded to treatment according to their 16-week computed tomography (CT) were assessed for eligibility for the FOCUS4-N comparison. In addition to the registration eligibility criteria, patients were required to have a baseline randomly assigned CT scan performed within 4 weeks prerandomization; a minimum 3-week washout period between the last chemotherapy or biologic therapy dose and the first capecitabine dose; adequate renal (creatinine clearance &gt; 50 mL/min) and liver function; and a WHO performance status of 0-2. Patients who were eligible for either FOCUS4-N or a molecularly stratified trial were offered entry into either and given the option of which study to participate in, followed by appropriate consent.</p>
                <p>In the first phase of FOCUS4 between January 2014 and June 2017, patients with raised baseline platelet count (thrombocytosis) were considered ineligible on the basis of previous data from the COIN trial (which indicated a significant survival detriment in this patient group receiving an intermittent strategy).<sup><xref rid="b1" ref-type="bibr">1</xref></sup> A subsequent individual patient data meta-analysis of phase II or III intermittent strategy trials did not confirm the observation from COIN.<sup><xref rid="b8" ref-type="bibr">8</xref></sup> Thus, between June 2017 and March 2020, eligibility criteria were adapted, allowing inclusion of this patient group with thrombocytosis.</p>
              </sec>
              <sec sec-type="methods">
                <title>Trial Procedures</title>
                <p>Patients randomly assigned to capecitabine were asked to continue taking the drug until disease progression, death, or intolerable toxicity. Capecitabine was dosed according to standard guidelines, orally twice daily for 14 days followed by a 7-day rest period without capecitabine tablets.</p>
                <p>Patient tumor status was assessed every 8 weeks by CT scan reviewed at the treating hospital site according to RECIST version 1.1.<sup><xref rid="b9" ref-type="bibr">9</xref></sup> Toxicities and symptoms were assessed locally every 4 weeks from random assignment or start of treatment using NCI CTCAE (version 3.0). Patients were followed until progressive disease, at which point the patient was recommended to restart first-line systemic therapy.</p>
                <p>Treatment was stopped for grade ≥ 3 toxic effects or persistent toxicities judged medically important or not tolerated by the patient, until the toxicity resolved to grade 1 or better. After stopping treatment, capecitabine could be reinitiated at a reduced dose. Any stoppage for ≥ 28 days was not permitted, with the patient discontinued from trial therapy but remaining under follow-up.</p>
                <p>QoL data using EQ-5D were collected at random assignment, every 8 (7-9) weeks until progression, 4 weeks after end of trial treatment, 3 months after progression, and then every 6 months.</p>
              </sec>
              <sec sec-type="methods">
                <title>Statistical Methods</title>
                <sec>
                  <title>Treatment allocation.</title>
                  <p>Patients were allocated to capecitabine or AM by a centrally managed telephone service at the MRC Clinical Trials Unit at University College London, using a 1:1 allocation ratio by minimization with a random element of 20%. Minimization factors were treating hospital site, primary tumor site (right colon, left colon, or rectum), WHO performance status (0, 1, or 2), 16-week CT scan result (stable disease and partial or complete response), number of metastatic sites (none, one, or two or more), and first-line therapy regimen (fluorouracil, capecitabine, or neither; both oxaliplatin and irinotecan, irinotecan only, or neither; and cetuximab or panitumumab, bevacizumab, or no monoclonal antibody).</p>
                </sec>
                <sec>
                  <title>Outcome measures.</title>
                  <p>The primary FOCUS4-N outcome was PFS, defined as time from random assignment to either disease progression (according to RECIST criteria) or death from any cause. Patients without a PFS event were censored at the time of their last recorded CT scan. OS was a secondary outcome, defined as time from random assignment to death from any cause with patients censored at last recorded disease assessment, blood measurement, or anticancer treatment. Other secondary outcomes included safety, toxicity, QoL, and tumor response. QoL was analyzed using mixed-effects linear modeling with patient-level random intercepts and time slopes, with differences by the treatment arm tested by evaluating the area under the curve from the model.</p>
                </sec>
                <sec>
                  <title>Sample size calculation.</title>
                  <p>The FOCUS4-N target sample size was calculated using the Analysis of Resources for Trials program implemented in Stata software. Given that the recruitment rate into FOCUS4-N was dependent on the availability of other molecular comparisons, failure of biomarker testing, or patient choice, exact recruitment figures were unknown at the trial commencement. Various scenarios were used to estimate the recruitment rate over 5 years, and we assumed a 4-month median PFS in the AM arm (on the basis of COIN trial data). A total of 644 patients (635 events) would provide 80% power of detecting a hazard ratio (HR) of 0.8 at the two-sided 5% significance level.</p>
                  <p>In March 2020, the COVID-19 pandemic resulted in temporary closure of FOCUS4 to new recruitment. Following Independent Data Monitoring Committee review and recommendation, a decision was taken to close recruitment permanently in April 2020 as trial funding was nearing its end. A previous review of the implications of reduced recruitment on the statistical power of FOCUS4-N had been considered by our funders who recommended that, despite reduced power, the trial should close in 2020 and report the data accrued up to that point. Furthermore, at analysis, it became clear that the observed HR was substantially more extreme than the target HR on which we based our original sample size.</p>
                </sec>
                <sec>
                  <title>Statistical analysis.</title>
                  <p>All analyses were performed according to a predefined statistical analysis plan agreed before database lock. We analyzed using Stata statistical software, version 16.1 (Stata Corporation, TX). The primary analysis was performed according to intention-to-treat with a secondary per-protocol analysis defined by patients who completed at least one cycle of trial treatment (≥ 28 days). Patients were censored according to the following criteria. For survival status, we censored patients on the date that they were last known to be alive, either via collection of prescription from their hospital pharmacy or attendance at a follow-up visit or CT scan. For PFS, we censored patients without progression on the date of the last CT scan showing no progression. For patients who died before any follow-up visit or CT scan, we used the date of death as the date of the event and assumed death without progression, provided that the death occurred within 3 months of random assignment or any previous scan confirming no progression.</p>
                  <p>Kaplan-Meier curves were used to present survival data and Cox regression modeling to estimate HRs between randomized groups. Unadjusted HRs and the ones adjusted for the stratification factors used to minimize patients into allocated groups (primary analysis) were estimated. A further analysis also adjusted for resection status, timing of metastatic disease, alkaline phosphatase, white blood cell count, age of tumor sample, and use of aspirin at baseline. Deviation from nonproportional hazards was assessed using regression of scaled Schoenfeld residuals against the log of time.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec>
                <title>Recruitment and Compliance</title>
                <p>Across 88 UK hospitals, between January 2014 and March 2020, 1,434 patients were registered into FOCUS4, of whom 924 underwent successful biomarker assessment and completed 16 weeks of first-line therapy with either stable or responding disease (Data Supplement). Of these patients, 254 were randomly assigned to FOCUS4-N (Fig <xref rid="fig1" ref-type="fig">1</xref>), 127 to AM and 127 to maintenance capecitabine. Baseline demographic and clinical characteristics were well-balanced between the study arms (Table <xref rid="tbl1" ref-type="table">1</xref> and Appendix Table A<xref rid="tblA1" ref-type="table">1</xref>, online only). Most patients had widespread synchronous metastatic disease with about half having an unresected primary tumor. A right-sided primary tumor location was present in about one third. The majority were treated with doublet chemotherapy (irinotecan-based 57%) without a monoclonal antibody (as bevacizumab is not reimbursed in the United Kingdom). The Data Supplement shows induction chemotherapy for all patients in FOCUS4, and the Data Supplement shows disease response to induction chemotherapy on the basis of biomarker subgroup. The molecular characteristics are shown in Table <xref rid="tbl1" ref-type="table">1</xref> (and the Data Supplement for all FOCUS4 participants), showing that only 37% had an <italic toggle="yes">RAS</italic> wild-type tumor reflecting NHS England policy of not allowing treatment breaks for patients on epidermal growth factor receptor monoclonal antibodies.</p>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Flow diagram showing patient flow through the FOCUS4-N trial. CR, complete response; PR, partial response; SD, stable disease.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g001" position="float"/>
                </fig>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Baseline Characteristics for FOCUS4-N</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g002" position="float"/>
                </table-wrap>
                <p>Compliance with randomized allocation was good with only one patient in the AM arm receiving capecitabine approximately 6 months before progression. Patients in the capecitabine arm received a median of four cycles (interquartile range, 2-8).</p>
              </sec>
              <sec>
                <title>Primary Outcome: PFS</title>
                <p>There were 122 of 127 PFS events in the AM arm and 117 of 127 in the capecitabine arm. The median PFS in the capecitabine arm was 3.88 months (95% CI, 3.65 to 4.37) and 1.87 months (95% CI, 1.81 to 2.14) in the AM arm. Unadjusted and adjusted HRs were 0.44 (95% CI, 0.33 to 0.57), <italic toggle="yes">P</italic> &lt; .0001 and 0.40 (95% CI, 0.21 to 0.75), <italic toggle="yes">P</italic> &lt; .0001, respectively. Figure <xref rid="fig2" ref-type="fig">2</xref> shows Kaplan-Meier curves. Per-protocol analyses demonstrated very similar findings; unadjusted and adjusted HRs were 0.42 (95% CI, 0.32 to 0.55), <italic toggle="yes">P</italic> &lt; .0001 and 0.38 (95% CI, 0.28 to 0.51), <italic toggle="yes">P</italic> &lt; .0001, respectively. There was no evidence to suggest deviation from the proportional hazards assumption (<italic toggle="yes">P</italic> = .084).</p>
                <fig position="float" id="fig2" fig-type="figure">
                  <label>FIG 2.</label>
                  <caption>
                    <p>Kaplan-Meier curve for PFS in FOCUS4-N. Cox regression HR, adjusted for minimization factors = 0.40 (95% CI, 0.21 to 0.75), <italic toggle="yes">P</italic> &lt; .0001. Minimization factors: location of primary tumor (left, right, and rectum), baseline WHO performance status, baseline disease assessment, No. of metastases, first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody), and biomarker cohort, stratified for FOCUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; PFS, progression-free survival.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g003" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>OS</title>
                <p>There were 90 of 127 deaths in the AM arm and 99 of 127 deaths in the capecitabine arm. The median time to death was 15.2 months (95% CI, 12.1 to 18.5) in the AM arm versus 14.8 months (95% CI, 23.7 to 18.6) in the capecitabine arm, with no survival difference between the arms; unadjusted and adjusted HRs were 1.00 (95% CI, 0.75 to 1.33), <italic toggle="yes">P</italic> = .98 and 0.93 (95% CI, 0.69 to 1.27), <italic toggle="yes">P</italic> = .66, respectively. Kaplan-Meier curves are presented in Figure <xref rid="fig3" ref-type="fig">3</xref>. There was no evidence to suggest deviation from the proportional hazards assumption (<italic toggle="yes">P</italic> = .58).</p>
                <fig position="float" id="fig3" fig-type="figure">
                  <label>FIG 3.</label>
                  <caption>
                    <p>Kaplan-Meier curve for OS in FOCUS4-N. Cox regression HR, adjusted for minimization factors = 0.93 (95% CI, 0.69 to 1.27), <italic toggle="yes">P</italic> = .66. Minimization factors: location of primary tumor (left, right, and rectum); baseline WHO performance status; baseline disease assessment; No. of metastases; first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody); and biomarker cohort, stratified for FOCUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; OS, overall survival.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g004" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Subgroup Analyses</title>
                <p>Preplanned subgroup analysis for PFS (Fig <xref rid="fig4" ref-type="fig">4</xref>A) suggested better PFS with a maintenance strategy in left-sided tumors (HR 0.38 <italic toggle="yes">v</italic> 0.56 for right-sided, interaction <italic toggle="yes">P</italic> = .13), and a similar observation was seen with OS (HR 0.82 for left-sided <italic toggle="yes">v</italic> 1.37 for right-sided, interaction <italic toggle="yes">P</italic> = .076; Fig <xref rid="fig4" ref-type="fig">4</xref>B). There was a suggestion that patients with tumoral loss of phosphatase and tensin homolog and <italic toggle="yes">PIK3CA</italic> mutations may show less benefit from maintenance capecitabine than other molecular subgroups (PFS HR 0.74, OS HR 1.47), although this was not statistically significant. For OS, the only other notable subgroup effect was that those with stable disease at random assignment appeared to benefit from maintenance capecitabine, whereas those with partial response did not (OS HR 0.63 and 1.42, respectively, interaction <italic toggle="yes">P</italic> = .005; Fig <xref rid="fig4" ref-type="fig">4</xref>B). Swimmer plots show the distribution of individual patient PFS duration and timing of CT scans by left- versus right-sided disease (Appendix Fig A<xref rid="figA1" ref-type="fig">1</xref>, online only).</p>
                <fig position="float" id="fig4" fig-type="figure">
                  <label>FIG 4.</label>
                  <caption>
                    <p>(A) Forest plot of subgroup analyses for PFS (unadjusted HRs). (B) Forest plot of subgroup analyses for OS (unadjusted HRs). AM, active monitoring; CAPOX, capeciteabine with oxaliplatin; Cet, cetuximab; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; HR, hazard ratio; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; PTEN, phosphatase and tensin homolog; PTL, primary tumor location.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g005" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Toxicity</title>
                <p>Cumulative toxicities were substantially less in the AM arm, with increased toxicities associated with capecitabine maintenance including diarrhea, dry skin, fatigue, nausea, and palmar-plantar erythema (PPE; Fig <xref rid="fig5" ref-type="fig">5</xref>). Ideally, a maintenance therapy should result in no toxicity. Incidence of grade zero as the worst toxicity reported per patient is therefore instructive and is as follows for AM and capecitabine maintenance, respectively: nausea 74% versus 67%, diarrhea 72% versus 46%, stomatitis 90% versus 77%, dry skin 83% versus 77%, PPE 87% versus 44%, and anemia 69% versus 54% (Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>, online only).</p>
                <fig position="float" id="fig5" fig-type="figure">
                  <label>FIG 5.</label>
                  <caption>
                    <p>Cumulative reported toxicity by randomized group: (A) active monitoring (n = 127) and (B) capecitabine (n = 127). G, grade; PPE, palmar-plantar erythema.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g006" position="float"/>
                </fig>
                <p>During the trial, 51% of patients who received capecitabine had at least one cycle delayed, 37% had a dose reduction, and 34% missed at least one dose (within a cycle). Fifty percent of capecitabine patients commenced at least four cycles, and 25% commenced at least eight cycles.</p>
              </sec>
              <sec>
                <title>QoL</title>
                <p>EQ-5D forms were completed in 93% (AM) and 90% (capecitabine) at baseline (prerandomization but postinduction chemotherapy). The Protocol (online only) mandated completion every 8 weeks until progression and 6-monthly thereafter; for analysis purposes, all available forms were forced into an 8-week schedule. On this basis, 63%, 45%, and 33% of randomly assigned patients had data available at 8, 16, and 24 weeks, respectively, with continuous decline thereafter. Modeling was applied to data up to 48 weeks, since data became too sparse beyond this. No notable differences were seen in mobility, self-care, usual activities, anxiety, and depression. There was a suggestion that pain and discomfort might have been experienced less within the capecitabine maintenance arm (<italic toggle="yes">P</italic> = .11, Fig <xref rid="fig6" ref-type="fig">6</xref>). This may be due to symptoms associated with increased rates of progression in the AM arm.</p>
                <fig position="float" id="fig6" fig-type="figure">
                  <label>FIG 6.</label>
                  <caption>
                    <p>Quality of life measured by EQ-5D by randomized group: (A) mobility: X<sup>2</sup> for AUC difference = 0.86(1), <italic toggle="yes">P</italic> = .35; (B) self-care: X<sup>2</sup> for AUC difference = 1.64(1), <italic toggle="yes">P</italic> = .20; (C) usual activities: X<sup>2</sup> for AUC difference = 0.06(1), <italic toggle="yes">P</italic> = .81; (D) pain and discomfort: X<sup>2</sup> for AUC difference = 2.49(1), <italic toggle="yes">P</italic> = .11; and (E) anxiety and depression: X<sup>2</sup> for AUC difference = 1.03(1), <italic toggle="yes">P</italic> = .31; AUC, area under the curve.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3693-g007" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>Choices on how to proceed with palliative treatment, in the large majority of patients with incurable mCRC, with stable or responding disease after 16 weeks of first-line therapy need careful consideration with the patient at the core. Discussions must be informed by the impact of receiving systemic anticancer therapy over the preceding period. This should include evaluation of the burden of toxicity and QoL, as well as the response to treatment. Pooled data from key phase II and III trials suggest minimal impact on OS from a maintenance or continuation strategy but do show the ability to delay a return to full combination therapy by implementation of a maintenance therapy. Notably, the FOCUS4-N data support the use of an oral only therapy (capecitabine) to extend PFS and delay a return to combination therapy by an average of two months. There is a clear cost to the patient for this improved PFS seen with maintenance capecitabine including worse toxicity in terms of diarrhea, fatigue, nausea, skin rash, and PPE albeit mostly at grade ≤ 2, and these factors should be used to further inform decision making. There was no difference in QoL scores between the two arms. It is notable that the swimmer plots (Appendix Fig A<xref rid="figA1" ref-type="fig">1</xref>) suggest that about a third of patients experience an extended PFS beyond 16 weeks with maintenance capecitabine, suggesting significant fluoropyrimidine sensitivity, while a third of patients demonstrate relative insensitivity to fluoropyrimidine monotherapy and may indicate a further need to explore predictive biomarkers of efficacy for this strategy. Preplanned subgroup analysis suggests that patients with stable disease at the end of 16-week induction period may gain a significant survival benefit from maintenance capecitabine, but this is not corroborated in other studies where the same phenomenon was assessed.<sup><xref rid="b8" ref-type="bibr">8</xref></sup></p>
              <p>Although this trial is underpowered to evaluate OS, it demonstrates very similar median values of 14.8 versus 15.2 months between the two arms with an HR of 0.93 (<italic toggle="yes">P</italic> = .66) when adjusted for minimization factors. It is informative to compare these data with those of CAIRO3, which compared an AM strategy with capecitabine plus bevacizumab maintenance with comparable effects on PFS (HR = 0.40, <italic toggle="yes">P</italic> &lt; .0001; cfFOCUS4-N adjusted HR = 0.40, <italic toggle="yes">P</italic> &lt; .0001) and nonsignificant OS effect (HR = 0.83, <italic toggle="yes">P</italic> = .06).<sup><xref rid="b4" ref-type="bibr">4</xref></sup> Cross-trial comparisons carry notable caveats and must be undertaken with caution as CAIRO3 included patients with better prognosis than FOCUS4-N and both their median PFS and cycle number on maintenance therapy were approximately double those of ours. However, it does suggest that the main driver of PFS improvement when using capecitabine plus bevacizumab is the capecitabine. Individual patient data meta-analysis has also shown no OS benefit from current maintenance therapy strategies.<sup><xref rid="b8" ref-type="bibr">8</xref></sup></p>
              <p>On the basis of a subgroup analysis from the much larger phase III COIN study,<sup><xref rid="b1" ref-type="bibr">1</xref></sup> which demonstrated a survival detriment in patients with a baseline thrombocytosis receiving a complete treatment break (HR = 1.55; <italic toggle="yes">P</italic> = .0018), we elected not to recruit patients with baseline thrombocytosis to the FOCUS4 trial program from January 2014 to June 2017. Wishing to validate or refute this finding, we undertook an individual patient data meta-analysis to assess thrombocytosis as a predictive marker of the benefits or otherwise of an intermittent or continuous therapy strategy.<sup><xref rid="b8" ref-type="bibr">8</xref></sup> This evaluation did not validate our COIN finding on thrombocytosis, and thus, trial eligibility was adapted to allow these patients to enroll. Within FOCUS4-N overall, 3% (n = 8) of patients had baseline thrombocytosis, and thus, our study is underpowered to explore this predictive phenomenon further. Because of our conservative approach, FOCUS4-N under-represents approximately 25% of patients with mCRC who typically have thrombocytosis at baseline, a known worse prognosis group. However, given our findings in the individual patient data meta-analysis, we do not feel that this undermines our more general conclusions, which are independent of baseline platelet count.</p>
              <p>Owing to funding restrictions in the UK National Health Service, bevacizumab is not routinely available for patients with mCRC, and in patients with <italic toggle="yes">RA</italic>S wild-type tumors, epidermal growth factor receptor monoclonal antibodies are only available in the first-line setting, with restrictions in England preventing treatment interruption of cetuximab/panitumumab for longer than 6 weeks. Additionally, during the FOCUS4-D trial recruitment period,<sup><xref rid="b10" ref-type="bibr">10</xref></sup> patients with <italic toggle="yes">RAS</italic> wild-type and <italic toggle="yes">BRAF</italic> wild-type tumors were eligible for random assignment and were preferentially recruited into that trial. These factors make for a selective group of patients recruited to FOCUS4-N during that time. From a molecular perspective, 59% of patients randomly assigned in the FOCUS4-N trial had an <italic toggle="yes">RAS</italic> mutation and 15% a <italic toggle="yes">BRAF</italic> mutation. Reassuringly, the Forest plots (Figs <xref rid="fig4" ref-type="fig">4</xref>A and <xref rid="fig4" ref-type="fig">4</xref>B) do not show any significant differences in PFS or OS on the basis of these molecular criteria.</p>
              <p>In conclusion, despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients entering treatment de-escalation after 16 weeks of induction therapy for mCRC. If maintenance therapy is selected following consideration of the advantages and disadvantages in consultation with a particular patient, capecitabine without bevacizumab may be used to extend PFS, in the interval after doublet or triplet therapy, essentially doubling the period before recommencing full-dose induction therapy. Notably, these data also provide tools to best inform the dialogue between patients and clinicians on the pros and cons of the different approaches and their trade-offs.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>The FOCUS4 Trial Investigators full list can be found in <xref rid="app1" ref-type="app">Appendix 1</xref>.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p>See accompanying editorial on page <related-article related-article-type="companion" ext-link-type="doi" id="ra1" xlink:href="10.1200/JCO.21.01999">3656</related-article></p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by Cancer Research UK and the National Institute for Health Research (NIHR).</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="other">
                <p>
                  <ext-link xlink:href="https://www.isrctn.com/ISRCTN90061546" ext-link-type="uri">ISRCTN#90061546</ext-link>
                </p>
              </fn>
            </fn-group>
            <fn-group>
              <fn id="afn1" fn-type="equal" specific-use="equal">
                <label>*</label>
                <p>R.A.A. and D.F. are joint first authors, L.C.B. and T.S.M. are joint last authors.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>Individual deidentified participant data (including data dictionaries) can be shared upon appropriate application to the MRC CTU at any time from full publication. Study protocols and statistical analysis plan have been provided in the Data Supplement with this manuscript. Going forward, it is proposed that data will be shared with an appropriate international collaborative repository to enable future IPD meta-analysis.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Richard A. Adams, David J. Fisher, Janet Graham, Matthew Seymour, Richard Kaplan, Mahesh Parmar, Philip Quirke, Harpreet Wasan, Kai-Keen Shiu, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan</p>
              <p><bold>Financial support:</bold> Janet Graham, Philip Quirke</p>
              <p><bold>Administrative support:</bold> Janet Graham, Richard Kaplan, Harpreet Wasan</p>
              <p><bold>Provision of study materials or patients:</bold> Janet Graham, Matthew Seymour, Susan D. Richman, Philip Quirke, Fiona Collinson, Harpreet Wasan, Leslie Samuel, Richard H. Wilson</p>
              <p><bold>Collection and assembly of data:</bold> Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Susan D. Richman, Rachel Butler, Stephen Falk, Kai-Keen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan</p>
              <p><bold>Data analysis and interpretation:</bold> Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Mahesh Parmar, Philip Quirke, Ewan Brown, Fiona Collinson, Stephen Falk, Harpreet Wasan, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="disclosures">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="http://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Richard A. Adams</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Merck Serono, Servier, Amgen</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck Serono, Amgen, Servier, Bayer</p>
                    <p><bold>Speakers' Bureau:</bold> Merck Serono</p>
                    <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Servier, Amgen, Merck Serono, AstraZeneca</p>
                  </fn>
                  <fn id="con2" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Janet Graham</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Merck Serono, Bristol Myers Squibb, Nucana, Bayer</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck KGaA</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Nucana</p>
                  </fn>
                  <fn id="con3" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Jenny F. Seligmann</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Pierre Fabre, Merck Serono, Servier</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pierre Fabre, Roche Molecular Diagnostics</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Bristol Myers Squibb/Medarex</p>
                  </fn>
                  <fn id="con4" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Matthew Seymour</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Amgen, AstraZeneca</p>
                  </fn>
                  <fn id="con5" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Richard Kaplan</bold>
                    </p>
                    <p><bold>Research Funding:</bold> AstraZeneca</p>
                  </fn>
                  <fn id="con6" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Mahesh Parmar</bold>
                    </p>
                    <p><bold>Research Funding:</bold> AstraZeneca, Astellas Pharma, Janssen, Clovis Oncology</p>
                  </fn>
                  <fn id="con7" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Philip Quirke</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Roche</p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche, Adlai Nortye, Avacta Life Sciences, Amgen, Bayer</p>
                    <p><bold>Research Funding:</bold> Roche, GeneFirst, ONI</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Roche have filed a patent jointly with my University</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche, Bayer, Amgen</p>
                  </fn>
                  <fn id="con8" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Rachel Butler</bold>
                    </p>
                    <p><bold>Speakers' Bureau:</bold> Bayer, Pfizer, Roche, AstraZeneca, MSD, Illumina, Lilly, Novartis, Amgen, Boehringer Ingelheim</p>
                  </fn>
                  <fn id="con9" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Ewan Brown</bold>
                    </p>
                    <p><bold>Research Funding:</bold> MSD Oncology</p>
                  </fn>
                  <fn id="con10" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Fiona Collinson</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Bristol Myers Squibb</p>
                  </fn>
                  <fn id="con11" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Stephen Falk</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> GlaxoSmithKline</p>
                    <p><bold>Speakers' Bureau:</bold> Merck Serono, Servier, Amgen</p>
                    <p><bold>Research Funding:</bold> Gilead Sciences</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Celgene</p>
                    <p><bold>Other Relationship:</bold> Servier</p>
                  </fn>
                  <fn id="con12" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Harpreet Wasan</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Merck KGaA, Celgene, Sirtex Medical, Servier, Array BioPharma, Roche/Genentech, ERYTECH Pharma, Incyte, Zymeworks</p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche Pharma AG, ERYTECH Pharma, Shire, Incyte, Sirtex Medical, Pierre Fabre, Pfizer, Bayer</p>
                    <p><bold>Speakers' Bureau:</bold> Sirtex Medical, Celgene, Merck KGaA, Servier, Incyte</p>
                    <p><bold>Research Funding:</bold> Sirtex Medical, Merck KGaA, Pfizer, Merck Sharp &amp; Dohme</p>
                  </fn>
                  <fn id="con13" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Kai-Keen Shiu</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Merck Serono, MSD Oncology, Innovent Biologics, Servier, Daiichi Sankyo Europe GmbH</p>
                    <p><bold>Consulting or Advisory Role:</bold> MSD Oncology, Roche, Mirati Therapeutics</p>
                    <p><bold>Research Funding:</bold> MSD Oncology, Roche</p>
                  </fn>
                  <fn id="con14" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Gary Middleton</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> BMS, D2G, MSD</p>
                    <p><bold>Speakers' Bureau:</bold> Roche, BMS, Servier, PierreFabre, AZ</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> BMS</p>
                  </fn>
                  <fn id="con15" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Leslie Samuel</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Servier</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck</p>
                    <p><bold>Research Funding:</bold> Merck, Array BioPharma, Tesaro, Servier, Hutchison MediPharma</p>
                  </fn>
                  <fn id="con16" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Richard H. Wilson</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Servier, Amgen, Bristol Myers Squibb</p>
                    <p><bold>Consulting or Advisory Role:</bold> Amgen, CV6 Therapeutics, Pierre Fabre, Amphista Therapeutics, Nucana</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Amgen, Pierre Fabre</p>
                  </fn>
                  <fn id="con17" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Louise C. Brown</bold>
                    </p>
                    <p><bold>Research Funding:</bold> AstraZeneca</p>
                  </fn>
                  <fn id="con18" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Timothy S. Maughan</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Vertex, Pierre Fabre</p>
                    <p><bold>Research Funding:</bold> AstraZeneca, PsiOxus Therapeutics, Merck KgAA, Almac Diagnostics</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Richard A. Adams</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Merck Serono, Servier, Amgen</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck Serono, Amgen, Servier, Bayer</p>
                  <p><bold>Speakers' Bureau:</bold> Merck Serono</p>
                  <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Servier, Amgen, Merck Serono, AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Janet Graham</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Merck Serono, Bristol Myers Squibb, Nucana, Bayer</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck KGaA</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Nucana</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jenny F. Seligmann</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Pierre Fabre, Merck Serono, Servier</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pierre Fabre, Roche Molecular Diagnostics</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Bristol Myers Squibb/Medarex</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Matthew Seymour</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Amgen, AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Richard Kaplan</bold>
                  </p>
                  <p><bold>Research Funding:</bold> AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Mahesh Parmar</bold>
                  </p>
                  <p><bold>Research Funding:</bold> AstraZeneca, Astellas Pharma, Janssen, Clovis Oncology</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Philip Quirke</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Roche</p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche, Adlai Nortye, Avacta Life Sciences, Amgen, Bayer</p>
                  <p><bold>Research Funding:</bold> Roche, GeneFirst, ONI</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Roche have filed a patent jointly with my University</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche, Bayer, Amgen</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Rachel Butler</bold>
                  </p>
                  <p><bold>Speakers' Bureau:</bold> Bayer, Pfizer, Roche, AstraZeneca, MSD, Illumina, Lilly, Novartis, Amgen, Boehringer Ingelheim</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Ewan Brown</bold>
                  </p>
                  <p><bold>Research Funding:</bold> MSD Oncology</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Fiona Collinson</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Bristol Myers Squibb</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Stephen Falk</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> GlaxoSmithKline</p>
                  <p><bold>Speakers' Bureau:</bold> Merck Serono, Servier, Amgen</p>
                  <p><bold>Research Funding:</bold> Gilead Sciences</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Celgene</p>
                  <p><bold>Other Relationship:</bold> Servier</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Harpreet Wasan</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Merck KGaA, Celgene, Sirtex Medical, Servier, Array BioPharma, Roche/Genentech, ERYTECH Pharma, Incyte, Zymeworks</p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche Pharma AG, ERYTECH Pharma, Shire, Incyte, Sirtex Medical, Pierre Fabre, Pfizer, Bayer</p>
                  <p><bold>Speakers' Bureau:</bold> Sirtex Medical, Celgene, Merck KGaA, Servier, Incyte</p>
                  <p><bold>Research Funding:</bold> Sirtex Medical, Merck KGaA, Pfizer, Merck Sharp &amp; Dohme</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Kai-Keen Shiu</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Merck Serono, MSD Oncology, Innovent Biologics, Servier, Daiichi Sankyo Europe GmbH</p>
                  <p><bold>Consulting or Advisory Role:</bold> MSD Oncology, Roche, Mirati Therapeutics</p>
                  <p><bold>Research Funding:</bold> MSD Oncology, Roche</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Gary Middleton</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> BMS, D2G, MSD</p>
                  <p><bold>Speakers' Bureau:</bold> Roche, BMS, Servier, PierreFabre, AZ</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> BMS</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Leslie Samuel</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Servier</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck</p>
                  <p><bold>Research Funding:</bold> Merck, Array BioPharma, Tesaro, Servier, Hutchison MediPharma</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Richard H. Wilson</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Servier, Amgen, Bristol Myers Squibb</p>
                  <p><bold>Consulting or Advisory Role:</bold> Amgen, CV6 Therapeutics, Pierre Fabre, Amphista Therapeutics, Nucana</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Amgen, Pierre Fabre</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Louise C. Brown</bold>
                  </p>
                  <p><bold>Research Funding:</bold> AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Timothy S. Maughan</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Vertex, Pierre Fabre</p>
                  <p><bold>Research Funding:</bold> AstraZeneca, PsiOxus Therapeutics, Merck KgAA, Almac Diagnostics</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <app-group>
              <app id="app1">
                <title>APPENDIX 1. Full Authorship List for the FOCUS4 Trial Investigators</title>
                <sec>
                  <title>Writing Committee for FOCUS4-N Trial</title>
                  <p>Adams R., Fisher D.J., Graham J., Seligmann J.F., Seymour M., Kaplan R., Yates E., Parmar M., Richman S.D., Quirke P., Butler R., Brown E., Collinson F., Falk S., Wasan H., Shiu K., Middleton G., Samuel L., Wilson R.H., Brown L.C., Maughan T.S.</p>
                </sec>
                <sec>
                  <title>Trial Management Group</title>
                  <p>Maughan T.S. (Chair), Wilson R., Adams R., Seymour M., Seligmann J.F., Graham J., Wasan H., Pope M., Pope J., Samuel L., Shiu K., Church D., Middleton G., Steward W., Twelves C., Wellman S., Hodgkinson E., Stoner N., Beety J., Duggleby K., Dutton G., MRC CTU team (below), laboratory staff (see below).</p>
                </sec>
                <sec>
                  <title>MRC CTU trial coordinating centre</title>
                  <p>Brown L.C., Kaplan R., Parmar M., Fisher D.J., Campos M., Yates E., Santana S., Fiddament A., Harper L., Bara A., Pugh C., Bathia R., Letchemanan K., Przybył B., Bhogal S., Gopalakrishnan G., Purvis C., Diaz-Montana C., Mohamed F., Townsend S., Cragg W., Masters L., Van Looy N., Rauchenberger M.</p>
                </sec>
                <sec>
                  <title>Laboratories</title>
                  <p>Quirke P., Richman S.D., Hemmings G., Davis J., Gallop N., Wilkinson L., Butler R., Roberts H., Jasani B., White R., Dodds R., James M., Morgan M.</p>
                </sec>
                <sec>
                  <title>Independent Data Monitoring Committee</title>
                  <p>Cameron D. (Chair), Souhami R., Peeters M., Billingham C., Griffiths G., Brown J.</p>
                </sec>
                <sec>
                  <title>Trial Steering Committee</title>
                  <p>Johnson P. (Chair), Rudd R., Whelan J., Russell A.</p>
                  <table-wrap position="anchor" id="tblu1">
                    <caption>
                      <p>Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076)</p>
                    </caption>
                    <graphic xlink:href="jco-39-3693-g008" position="float"/>
                  </table-wrap>
                  <fig position="anchor" id="figA1" fig-type="figure">
                    <label>FIG A1.</label>
                    <caption>
                      <p>Swimmer plot for FOCUS4-N, by location of primary tumor. CT, computed tomography.</p>
                    </caption>
                    <graphic xlink:href="jco-39-3693-g009" position="float"/>
                  </fig>
                  <table-wrap position="anchor" id="tblA1">
                    <label>TABLE A1.</label>
                    <caption>
                      <p>Baseline Characteristics of Laboratory Tests by Treatment Allocation for FOCUS4-N</p>
                    </caption>
                    <graphic xlink:href="jco-39-3693-g010" position="float"/>
                  </table-wrap>
                  <table-wrap position="anchor" id="tblA2">
                    <label>TABLE A2.</label>
                    <caption>
                      <p>Worst Toxicity Reported per Patient, by the Treatment Arm in FOCUS4-N</p>
                    </caption>
                    <graphic xlink:href="jco-39-3693-g011" position="float"/>
                  </table-wrap>
                </sec>
              </app>
            </app-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adams</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Meade</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Seymour</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>12</volume>
                  <fpage>642</fpage>
                  <lpage>653</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21641867</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>NCCN</collab>
                  </person-group>
                  <source>NCCN Guidelines for Patients: Colon Cancer</source>
                  <ext-link xlink:href="https://www2.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdf" ext-link-type="uri">https://www2.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Cutsem</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cervantes</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Adam</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>ESMO consensus guidelines for the management of patients with metastatic colorectal cancer</article-title>
                  <source>Ann Oncol</source>
                  <volume>27</volume>
                  <fpage>1386</fpage>
                  <lpage>1422</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27380959</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Simkens</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>van Tinteren</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>May</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group</article-title>
                  <source>Lancet</source>
                  <volume>385</volume>
                  <fpage>1843</fpage>
                  <lpage>1852</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25862517</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hegewisch-Becker</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Graeven</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Lerchenmuller</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>16</volume>
                  <fpage>1355</fpage>
                  <lpage>1369</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26361971</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sherman</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Lange</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Dahdaleh</surname>
                      <given-names>FS</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer</article-title>
                  <source>JAMA Oncol</source>
                  <volume>5</volume>
                  <fpage>236</fpage>
                  <lpage>242</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">30489611</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sonbol</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Mountjoy</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Firwana</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The role of maintenance strategies in metastatic colorectal cancer: A systematic review and network meta-analysis of randomized clinical trials</article-title>
                  <source>JAMA Oncol</source>
                  <volume>6</volume>
                  <fpage>e194489</fpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">31855256</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adams</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Goey</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Chibaudel</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis</article-title>
                  <source>Clin Cancer Rev</source>
                  <volume>99</volume>
                  <fpage>102226</fpage>
                  <year>2021</year>
                </mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eisenhauer</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Therasse</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bogaerts</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</article-title>
                  <source>Eur J Cancer</source>
                  <volume>45</volume>
                  <fpage>228</fpage>
                  <lpage>247</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19097774</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adams</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): A phase 2-3 randomised trial</article-title>
                  <source>Lancet Gastroenterol Hepatol</source>
                  <volume>3</volume>
                  <fpage>162</fpage>
                  <lpage>171</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29254887</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
